Enoxaparin Dosing for 88 kg Patient
For an 88 kg patient, Lovenox at 1 mg/kg equals 88 mg administered subcutaneously.
Dosing Calculation
The standard therapeutic dose of enoxaparin is 1 mg/kg based on actual body weight 1. For your 88 kg patient:
- 88 kg × 1 mg/kg = 88 mg subcutaneously
Administration Schedule by Indication
The frequency depends on the clinical indication 1:
VTE Treatment (DVT/PE)
- 88 mg every 12 hours (preferred for most patients), OR
- 132 mg once daily (1.5 mg/kg alternative dosing)
- Continue for minimum 5 days and until INR 2-3 on warfarin 2, 1
Unstable Angina/NSTEMI
- 88 mg every 12 hours with aspirin
- Continue 2-8 days until clinical stabilization 1
STEMI
- 30 mg IV bolus followed by 88 mg subcutaneously, then
- 88 mg every 12 hours (maximum 100 mg for first two doses only)
- Continue up to 8 days or hospital discharge 1
Critical Dosing Considerations
Renal Function
- Severe renal impairment (CrCl <30 mL/min): Reduce to 88 mg once daily (not every 12 hours) 1
- Moderate/mild impairment: No adjustment needed, but monitor closely for bleeding 1
Age Adjustments
- ≥75 years with STEMI: Omit IV bolus and reduce to 66 mg (0.75 mg/kg) every 12 hours 1
Obesity Considerations
While this 88 kg patient is not obese, it's worth noting that guidelines recommend using actual body weight without dose capping 3. However, emerging evidence suggests that in morbidly obese patients (BMI ≥40), standard 1 mg/kg dosing frequently produces supratherapeutic levels 4, 5, 6. For this 88 kg patient with presumably normal BMI, standard 1 mg/kg dosing is appropriate.
Monitoring
Routine anti-Xa monitoring is NOT recommended for patients with normal renal function and body weight 3, 1. The 2018 ASH guidelines explicitly state that providers should dose LMWH based on actual body weight without monitoring anti-factor Xa concentrations 3.
Common Pitfalls to Avoid
- Do not round to convenient vial sizes without clinical justification—use actual calculated dose
- Do not cap the dose at arbitrary limits (e.g., 100 mg) except for the first two doses in STEMI patients ≥75 years 1
- Do not use intramuscular administration—subcutaneous or IV only 1
- Do not mix with other injections when giving subcutaneously 1